Servier's sevasemten fails pivotal Becker muscular dystrophy trial

Servier said sevasemten, the Becker muscular dystrophy drug it acquired from Edgewise Therapeutics for $1.55 billion upfront in a deal announced in June, failed its pivotal GRAND CANYON trial, missing the primary endpoint and all secondary endpoints.

Why it matters: The failure lands five months after Servier paid $1.55 billion upfront for Edgewise's muscular dystrophy business, and it leaves Becker muscular dystrophy, a rare disease with no approved treatment, without the first targeted therapy the trial was powered to support.

Data as of Servier announcement of November 3, 2026, the primary source for the trial result; Servier disclosed no numerical efficacy data. Deal terms are from the companies' June 1, 2026 acquisition announcement as reported by Endpoints News on November 3, 2026. Developing item.

Servier announced on November 3 that topline results from GRAND CANYON, the 18-month global placebo-controlled pivotal trial of sevasemten in Becker muscular dystrophy, did not meet the primary endpoint, with no statistically significant benefit on the North Star Ambulatory Assessment, and that secondary endpoints were also not met, although the drug’s safety and tolerability profile remained favourable. Servier said the pivotal results are not aligned with certain findings in prior studies, including the Phase 2 CANYON study, and that it is conducting a comprehensive analysis of the dataset, with full results to be presented later. The readout comes five months after Servier agreed to acquire Edgewise Therapeutics’ muscular dystrophy business for $1.55 billion upfront plus up to $1.1 billion in milestones, a deal that closed in July.

Servier's sevasemten fails pivotal Becker muscular dystrophy trial

Sources